ReviewNanomedicine (London, England)2025
Considering the immunogenicity of PEG: strategies for overcoming issues with PEGylated nanomedicines.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives.Molecular cancer · 2026Review
- Recent advances in lipid nanoparticles for cancer vaccine delivery: Challenges and future perspectives.International journal of pharmaceutics: X · 2026Review
- Nanotechnology-Enabled Precision Therapy for Lung Cancer in Never-Smokers.Pharmaceutics · 2026Review
- Prospects and challenges of traditional Chinese medicine supramolecular nano-drug delivery systems in the treatment of cerebral ischemia.Frontiers in pharmacology · 2026Review
- Enabling organ- and injury-specific nanocarrier targetingNanoscale horizons · 2025Article
- Introducing Sulfur Ylides as Charge-Neutral Termini for Mitigating Poly(ethylene glycol) Antigenicity in Nanomedicine.JACS Au · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
In the field of nanomedicine, there is considerable familiarity with both the various applications of poly(ethylene glycol) (PEG) and the related topic of anti-PEG antibodies (anti-PEG Abs). The worldwide spread of mRNA-LNP vaccines has focused much attention on the sometimes problematic relationship between immune responses and the various possible pharmacological uses of PEG. In this paper, which is a perspective review, I summarize the properties of PEG, the properties of anti-PEG Abs, and the various methods for evaluating the relationship between these two factors. I then offer suggestions for addressing the adverse effects that anti-PEG Abs have on the medicinal power of PEGylated nanomedicines. Ultimately, by exploring important developments in the above areas, this review offers an organized, synthesized presentation of information that should prove useful for the development of nanomedicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.